Welcome to "Late-Stage" DSM based categorization of mental disorders
Zach Haigney
Hello! On the occasion of my recent appearance on the Business Trip Podcast, where I spoke with Greg Kubin of the Psychedelic Medicine Syndicate, I wan…
Zach Haigney
Hi, Thanks for checking in. In case this is your first time here, The Trip Report is a newsletter created by, me, Zach Haigney. It is an attempt to exp…
Zach Haigney
Dear Readers, It is time to think about the next chapter of The Trip Report. I have decided to take a hiatus from the 2-3 posts/week schedule that we'v…
Zach Haigney
Psychedelic News Roundup In Partnership with Lucid News Policy Can Psychedelics Help Save America? A Healthcare and bioethics group at Harvard Law scho…
Zach Haigney
There’s a tactic agreement that safety and efficacy are not going to be the barrier to rolling out psychedelic medicine— but rather, delivery will prov…
Zach Haigney
Field Trip IPO On Tuesday, Field Trip Psychedelics became the third publicly traded psychedelic company with at least a $100 million valuation behind M…
Zach Haigney
Jaguar makes one of the two FDA approved Botanical Drugs
Zach Haigney
On November 3rd Oregon voters will have the chance to vote for Measure 109, a state-regulated psilocybin therapy framework. It is the first state-level…
Zach Haigney
Numinus & Field Trip: A Tale of Two Strategies Announcements from Numinus and Field Trip highlight two different approaches and two different challenge…
Zach Haigney
With COMPASS Pathways' listing and early success on NASDAQ, a clear precedent is set. The premise of psychedelic medicine has been accepted by more ext…
Zach Haigney
Psychedelic Business News Roundup In Partnership with Lucid News UC Berkeley Center for the Science of Psychedelics “To the psychologist, the religious…
Zach Haigney